We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Reluctantly Reject Hemispherx’s CFS Candidate
FDA Advisers Reluctantly Reject Hemispherx’s CFS Candidate
December 21, 2012
The FDA’s Arthritis Drugs Advisory Committee (ADAC) reluctantly recommended against approval of Hemispherx Biopharma’s chronic fatigue syndrome (CFS) drug Ampligen.